AR072622A1 - Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas - Google Patents

Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas

Info

Publication number
AR072622A1
AR072622A1 ARP090102879A ARP090102879A AR072622A1 AR 072622 A1 AR072622 A1 AR 072622A1 AR P090102879 A ARP090102879 A AR P090102879A AR P090102879 A ARP090102879 A AR P090102879A AR 072622 A1 AR072622 A1 AR 072622A1
Authority
AR
Argentina
Prior art keywords
atoms
independently
denotes
cyc
tumors
Prior art date
Application number
ARP090102879A
Other languages
English (en)
Spanish (es)
Inventor
Emilie Rossignol
Dominique Swinnen
Hartmut Greiner
Guenter Hoelzemann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR072622A1 publication Critical patent/AR072622A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP090102879A 2008-07-29 2009-07-29 Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas AR072622A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08013574 2008-07-29

Publications (1)

Publication Number Publication Date
AR072622A1 true AR072622A1 (es) 2010-09-08

Family

ID=41009860

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102879A AR072622A1 (es) 2008-07-29 2009-07-29 Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas

Country Status (9)

Country Link
US (1) US8389554B2 (de)
EP (1) EP2307425B1 (de)
JP (1) JP2011529456A (de)
AR (1) AR072622A1 (de)
AU (1) AU2009275544B2 (de)
CA (1) CA2732186A1 (de)
ES (1) ES2470681T3 (de)
IL (1) IL210869A (de)
WO (1) WO2010012345A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2193133T3 (en) 2007-09-27 2015-10-05 Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
JP5615902B2 (ja) 2009-04-02 2014-10-29 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ）Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ Ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ（Ｃｎｉｏ） イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
EP2671885A1 (de) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-Oxadiazol- und Imidazo-Thiadiazolderivate
EP3515916B1 (de) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2-phosphatase-inhibitoren und verfahren zur verwendung davon
TWI848901B (zh) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3630770B1 (de) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazin-derivate als shp2-phosphatase-inhibitoren
WO2019067843A1 (en) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2
EP3755699A1 (de) * 2018-02-21 2020-12-30 Relay Therapeutics, Inc. Shp2-phosphatase-inhibitoren und verfahren zur verwendung davon
IL301106A (en) 2018-03-21 2023-05-01 Relay Therapeutics Inc SHP2 phosphatase inhibitors and methods of using them
CN112752761B (zh) * 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
WO2021061706A1 (en) 2019-09-24 2021-04-01 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of making and using the same
BR112022007404A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Compostos e composições para o tratamento de doenças parasíticas
WO2022053838A1 (en) * 2020-09-14 2022-03-17 The University Of Sussex Small molecule inhibitors of lemur tyrosine kinase 3
CN114195736B (zh) * 2021-12-30 2023-08-04 浙江闰土染料有限公司 2-氨基-5-溴-1,3,4-噻二唑的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US20090170845A1 (en) * 2006-04-13 2009-07-02 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
DK2193133T3 (en) * 2007-09-27 2015-10-05 Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS

Also Published As

Publication number Publication date
ES2470681T3 (es) 2014-06-24
IL210869A0 (en) 2011-04-28
EP2307425A1 (de) 2011-04-13
JP2011529456A (ja) 2011-12-08
AU2009275544A1 (en) 2010-02-04
EP2307425B1 (de) 2014-03-26
WO2010012345A1 (en) 2010-02-04
US8389554B2 (en) 2013-03-05
US20110130396A1 (en) 2011-06-02
AU2009275544B2 (en) 2013-09-12
IL210869A (en) 2014-01-30
CA2732186A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
AR072622A1 (es) Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas
AR113818A2 (es) Pirazolo-quinazolinas como inhibidores de proteína quinasa
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR110051A2 (es) Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR059087A1 (es) Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas.
AR037983A1 (es) Derivados de pirido [2,1-a] isoquinolina
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
PE20080263A1 (es) Compuestos de pirrolo-pirimidina y sus usos
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
BR112022012195A2 (pt) Derivados de piperidina bicíclico substituídos úteis como ativadores de células t
AR062427A1 (es) Derivados heteroarilo como inhibidores de citocina
DOP2014000055A (es) Derivados de pirrolopirimidina y purina
AR062696A1 (es) N-(1-hetaril- piperidin -4-il)- (het) arilamidas como moduladores del receptor ep2.
AR066543A1 (es) Derivados de piridazinona
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR053436A1 (es) Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
AR087841A1 (es) Derivados de tetrahidrotriazolopirimidina
UY28157A1 (es) Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos
MX2011011516A (es) Compuestos farmaceuticos.
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
AR046170A1 (es) Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina

Legal Events

Date Code Title Description
FB Suspension of granting procedure